MK-0608

• Description :

  MK-0608 is a potent and orally bioavailable inhibitor of HCV replication in vitro with an EC50 of 0.3 μM (EC90=1.3 μM) in the subgenomic-replicon assay[1].

• CAS Number :

  [443642-29-3]

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  HCV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/mk-0608.html

• Purity :

  99.81

• Solubility :

  DMSO : 250 mg/mL (ultrasonic)

• Smiles :

  OC[C@@H]1[C@@H](O)[C@](O)(C)[C@H](N2C=CC3=C2N=CN=C3N)O1

• Molecular Formula :

  C12H16N4O4

• Molecular Weight :

  280.28

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Carroll SS, et al. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother. 2009 Mar;53 (3) :926-34.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported